Investigating how MED1 affects androgen receptor activity in advanced prostate cancer
Role of MED1 in the AR-dependent transcription in advanced prostate cancer
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-10977344
This study is looking at a tough type of prostate cancer and how a protein called MED1 works with a hormone receptor that helps the cancer grow, with the goal of finding new treatments that could help patients by blocking this process.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10977344 on ClinicalTrials.gov |
What this research studies
This research focuses on advanced metastatic castration-resistant prostate cancer (CRPC), a severe form of cancer that is driven by androgen receptor (AR) signaling. The study aims to understand the role of a protein called MED1 in the interaction with AR and how this interaction can be disrupted by specific inhibitors. By examining the phosphorylation of MED1, the researchers hope to uncover new therapeutic strategies that could reverse the cancer's reliance on AR signaling. Patients may benefit from potential new treatments that target this mechanism.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced metastatic castration-resistant prostate cancer.
Not a fit: Patients with early-stage prostate cancer or those not resistant to androgen therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve outcomes for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in targeting androgen receptor signaling in prostate cancer, suggesting that this approach could be effective.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ASANGANI, IRFAN AHMED — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: ASANGANI, IRFAN AHMED
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.